Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Murray

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancerJonathan C Trent, Vicente Valero, Daniel J Booser, et al.
Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancerJames L Murray, Michael E Gillogly, Donna Przepiorka, et al.
Cancer|October 19, 2011
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancerStacy Moulder, Gregory Gladish, Joe Ensor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerFrancisco J Esteva, Vicente Valero, Daniel Booser, et al.
Hormones & Cancer|July 16, 2011
Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancerJie Qing Chen, Yi Bao, Jennifer Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 7, 2020
Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot studyKaren M Basen-Engquist, Margaret Raber, Cindy L Carmack, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
AIDS Research and Human Retroviruses|March 13, 2012
Identification of cellular proteins required for replication of human immunodeficiency virus type 1Natallia Dziuba, Monique R Ferguson, William A O'Brien, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancerJonathan C Trent, Vicente Valero, Daniel J Booser, et al.
Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancerJames L Murray, Michael E Gillogly, Donna Przepiorka, et al.
Cancer|October 19, 2011
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancerStacy Moulder, Gregory Gladish, Joe Ensor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerFrancisco J Esteva, Vicente Valero, Daniel Booser, et al.
Hormones & Cancer|July 16, 2011
Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancerJie Qing Chen, Yi Bao, Jennifer Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 7, 2020
Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot studyKaren M Basen-Engquist, Margaret Raber, Cindy L Carmack, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
AIDS Research and Human Retroviruses|March 13, 2012
Identification of cellular proteins required for replication of human immunodeficiency virus type 1Natallia Dziuba, Monique R Ferguson, William A O'Brien, et al.
Pageof 7